RVTY Stock Analysis: Revvity | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 12.691m USD | 12M Return: 10% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 150M
EPS Trend: 0.4%
Qual. Beats: 2
Rev. Trend: 48.5%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Revvity, Inc. (RVTY) is a U.S.-based health sciences company headquartered in Waltham, Massachusetts, providing instruments, reagents, software, and services across diagnostics and life sciences research. Its offerings span newborn and prenatal screening (covering conditions such as Down syndrome, hypothyroidism, and metabolic disorders), infectious disease testing, genomic workflow technologies, and drug discovery tools that leverage next-generation DNA sequencing and protein-coupled receptor platforms for oncology and immunodiagnostics.
The company sells under a broad portfolio of brand names-including AutoDELFIA, EUROIMMUN, BioLegend, Vanadis, ViaCord, and AlphaLISA-to a diverse customer base comprising pharmaceutical and biotechnology firms, clinical laboratories, academic and research institutions, public health authorities, and government agencies. Originally founded in 1937 as PerkinElmer, the business rebranded as Revvity in April 2023. As a constituent of the Life Sciences Tools & Services sub-industry, Revvity operates within a sector that supplies enabling technologies and consumables to a broad range of healthcare and biomedical research end markets, supporting recurring revenue through reagents, consumables, and service contracts.
- Newborn screening mandates fuel Diagnostics segment revenue growth
- China biosecurity law limits life sciences tools demand
- Pharma and biotech R&D spending recovery drives reagent and instrument orders
| Net Income: 241.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.12 > 1.0 |
| NWC/Revenue: 30.65% < 20% (prev 60.28%; Δ -29.63% < -1%) |
| CFO/TA 0.05 > 3% & CFO 571.4m > Net Income 241.0m |
| Net Debt (2.63b) to EBITDA (772.8m): 3.41 < 3 |
| Current Ratio: 1.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.9m) vs 12m ago -6.95% < -2% |
| Gross Margin: 51.44% > 18% (prev 54.35%; Δ -2.92% > 0.5%) |
| Asset Turnover: 23.83% > 50% (prev 22.41%; Δ 1.42% > 0%) |
| Interest Coverage Ratio: 3.83 > 6 (EBIT TTM 359.8m / Interest Expense TTM 93.9m) |
| A: 0.07 (Total Current Assets 2.13b - Total Current Liabilities 1.24b) / Total Assets 12.0b |
| B: 0.51 (Retained Earnings 6.09b / Total Assets 12.0b) |
| C: 0.03 (EBIT TTM 359.8m / Avg Total Assets 12.2b) |
| D: 1.49 (Book Value of Equity 7.18b / Total Liabilities 4.81b) |
| Altman-Z'' = 3.91 = AA |
| DSRI: 1.07 (Receivables 691.4m/617.4m, Revenue 2.90b/2.77b) |
| GMI: 1.06 (GM 54.35% / 51.44%) |
| AQI: 1.01 (AQ_t 0.77 / AQ_t-1 0.76) |
| SGI: 1.05 (Revenue 2.90b / 2.77b) |
| TATA: -0.03 (NI 241.0m - CFO 571.4m) / TA 12.0b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 112.29 with a total of 729,525 shares traded. Over the past week, the price has changed by -1.29%, over one month by +10.86%, over three months by +25.16% and over the past year by +9.97%.
Current recommended Stop Loss: 102.70 (which is 8.5% or 2.4 ATR below the current price).
Revvity has received a consensus analysts rating of 4.16. Therefore, it is recommended to buy RVTY.
- StrongBuy: 10
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 113.7 | 1.3% |
P/E Trailing = 54.6923
P/E Forward = 21.692
P/S = 4.3726
P/B = 1.7669
P/EG = 0.7165
Revenue TTM = 2.90b USD
EBIT TTM = 359.8m USD
EBITDA TTM = 772.8m USD
Long Term Debt = 2.63b USD (from longTermDebt, last quarter)
Short Term Debt = 575.8m USD (from shortTermDebt, last quarter)
Debt = 3.49b USD (from shortLongTermDebtTotal, last quarter) + Leases 142.3m
Net Debt = 2.63b USD (calculated: Debt 3.49b - CCE 860.3m)
Enterprise Value = 15.3b USD (12.7b + Debt 3.49b - CCE 860.3m)
Interest Coverage Ratio = 3.83 (Ebit TTM 359.8m / Interest Expense TTM 93.9m)
EV/FCF = 31.02x (Enterprise Value 15.3b / FCF TTM 493.9m)
FCF Yield = 3.22% (FCF TTM 493.9m / Enterprise Value 15.3b)
FCF Margin = 17.02% (FCF TTM 493.9m / Revenue TTM 2.90b)
Net Margin = 8.30% (Net Income TTM 241.0m / Revenue TTM 2.90b)
Gross Margin = 51.44% ((Revenue TTM 2.90b - Cost of Revenue TTM 1.41b) / Revenue TTM)
Gross Margin QoQ = 54.51% (prev 43.80%)
Tobins Q-Ratio = 1.28 (Enterprise Value 15.3b / Total Assets 12.0b)
Interest Expense / Debt = 2.69% (Interest Expense 93.9m / Debt 3.49b)
Taxrate = 9.10% (24.2m / 265.9m)
NOPAT = 327.1m (EBIT 359.8m * (1 - 9.10%))
Current Ratio = 1.72 (Total Current Assets 2.13b / Total Current Liabilities 1.24b)
Debt / Equity = 0.49 (Debt 3.49b / totalStockholderEquity, last quarter 7.18b)
Debt / EBITDA = 3.41 (Net Debt 2.63b / EBITDA 772.8m)
Debt / FCF = 5.33 (Net Debt 2.63b / FCF TTM 493.9m)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.98% (Net Income 241.0m / Total Assets 12.0b)
RoE = 3.28% (Net Income TTM 241.0m / Total Stockholder Equity 7.34b)
RoCE = 3.61% (EBIT 359.8m / Capital Employed (Equity 7.34b + L.T.Debt 2.63b))
RoIC = 2.92% (NOPAT 327.1m / Invested Capital 11.2b)
WACC = 8.31% (E(12.7b)/V(16.2b) * Re(9.93%) + D(3.49b)/V(16.2b) * Rd(2.69%) * (1-Tc(0.09)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -4.27%
[DCF] Terminal Value 74.62% ; FCFF base≈506.0m ; Y1≈483.6m ; Y5≈464.0m
[DCF] Fair Price = 41.81 (EV 7.30b - Net Debt 2.63b = Equity 4.66b / Shares 111.6m; r=8.35% [WACC [floored]]; 5y FCF grow -5.76% → 2.50% )
EPS Correlation: 0.40 | EPS CAGR: 0.02% | SUE: 1.14 | # QB: 2
Revenue Correlation: 48.51 | Revenue CAGR: 1.14% | SUE: 2.06 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.22 | Chg30d=+0.30% | Revisions=-17% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.31 | Chg30d=-0.08% | Revisions=-17% | Analysts=12
EPS current Year (2026-12-31): EPS=5.25 | Chg30d=+0.08% | Revisions=+40% | GrowthEPS=+3.7% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=5.83 | Chg30d=+0.30% | Revisions=-80% | GrowthEPS=+11.1% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -52% (up=4, down=16)